Release Date: December 10, 2022
Expiration Date: March 2, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is directed toward hematologists, pediatricians, emergency medicine clinicians, pain management specialists, specialty NPs, PAs, RNs, and other HCPs involved in the management of patients with SCD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline the important components of successful pain management in patients with sickle cell disease
- Evaluate the use of approved and emerging therapies alone or in combination in the management of patients with sickle cell disease
- Recognize the challenges of treating disease-related complications and comorbid conditions in patients with sickle cell disease
- Support the transition from pediatric to adult care based on an understanding of the evolving needs of patients with sickle cell disease
- Implement individualized and holistic management strategies in coordination with other specialists and healthcare providers involved with the patient
Biree Andemariam, MD
Professor of Medicine
American Red Cross Endowed Chair in Transfusion Medicine
UConn School of Medicine
UConn Health
Farmington, CT
Disclosures: Grant/Research Support: Forma Therapeutics, Global Blood Therapeutics, Novartis; Consultant: Agios, Aruvant, bluebird bio, CRISPR Therapeutics, CVS Accordant, Emmaus Life Sciences, Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk, Terumo BCT, Vertex Pharmaceuticals.
Raffaella Colombatti, MD, PhD
Pediatric Hematologist
University of Padua
Padua, Italy
Disclosures: Grant/Research Support: bluebird bio, Global Blood Therapeutics; Consultant: Global Blood Therapeutics, Novo Nordisk; Speakers’ Bureau: Addmedica, Forma Therapeutics, Global Blood Therapeutics, Novo Nordisk, Vertex Pharmaceuticals.
Modupe Idowu, MD
Professor of Medicine
Division of Hematology
Director, Benign Hematology Section
Associate Program Director/Hematology/Oncology Fellowship
McGovern Medical School
UTHealth Houston
Houston, TX
Disclosures: Grant/Research Support: Agios, Forma Therapeutics, Global Blood Therapeutics, NIH, Novartis, Pfizer; Consultant: Global Blood Therapeutics, Novartis; Speakers’ Bureau: Global Blood Therapeutics
Nirmish Shah, MD
Associate Professor of Medicine and Pediatrics
Director of Sickle Cell Transition Program
School of Medicine
Duke University
Durham, NC
Nirmish Shah, MD has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
